Clinical Implications for Germline PTEN Spectrum Disorders

• Autores: Joanne Ngeow, Kaitlin Sesock, Charis Eng
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 46, Nº. 2, 2017 (Ejemplar dedicado a: Genetics of Endocrine Disorders), págs. 503-517
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Patients with PTEN hamartoma tumor syndrome (PHTS) may present to a variety of different subspecialties with benign and malignant clinical features. They have increased lifetime risks of breast, endometrial, thyroid, renal, and colon cancers, as well as neurodevelopmental disorders such as autism spectrum disorder. Patients and affected family members can be offered gene-directed surveillance and management. Patients who are unaffected can be spared unnecessary investigations. With longitudinal follow-up, we are likely to identify other non-cancer manifestations associated with PHTS such as metabolic, immunologic, and neurologic features.